N-dansyl-3-aminobenzeneboronic acid: potent serine protease inhibitor; fluorescent boronic acid which reversibly binds to bacterial cell walls; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 150643 |
| CHEMBL ID | 140740 |
| SCHEMBL ID | 593250 |
| MeSH ID | M0102315 |
| Synonym |
|---|
| 3-(dansylamino)phenylboronic acid, bioreagent, suitable for fluorescence, >=98.0% (hplc) |
| m(dansylamidophenyl)boronic acid |
| CHEMBL140740 , |
| [3-[[5-(dimethylamino)naphthalen-1-yl]sulfonylamino]phenyl]boronic acid |
| 3-(5-(dimethylamino)naphthalene-1-sulfonamido)phenylboronic acid |
| bdbm50067898 |
| 75806-94-9 |
| A838516 |
| [3-[[5-(dimethylamino)-1-naphthyl]sulfonylamino]phenyl]boronic acid |
| n-dansyl-3-aminobenzeneboronic acid |
| n-(5-dimethylamino-1-naphthalensulfonyl)-3-aminobenzeneboronic acid |
| einecs 278-319-1 |
| boronic acid, (3-(((5-(dimethylamino)-1-naphthalenyl)sulfonyl)amino)phenyl)- |
| (3-(((5-(dimethylamino)-1-naphthyl)sulphonyl)amino)phenyl)metaboric acid |
| FT-0641576 |
| 3-(dansylamino)phenylboronic acid |
| AKOS015894027 |
| SCHEMBL593250 |
| 3-(5-dimethylaminonaphthalene-1-sulfonylamino)benzeneboronic acid |
| fb-1 |
| TYXMKSYBCDTGDU-UHFFFAOYSA-N |
| 3-dansylaminophenylboronic acid |
| DTXSID00226723 |
| m-dansylaminophenyl boronic acid |
| (3-(5-(dimethylamino)naphthalene-1-sulfonamido)phenyl)boronic acid |
| STARBLD0016827 |
| SB83643 |
| CS-0031601 |
| HY-W019810 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chymotrypsinogen A | Bos taurus (cattle) | IC50 (µMol) | 100.0000 | 0.9800 | 4.0560 | 7.2000 | AID36989 |
| Beta-lactamase | Escherichia coli K-12 | IC50 (µMol) | 5.0000 | 0.0150 | 2.4657 | 8.0000 | AID38396 |
| Beta-lactamase | Escherichia coli K-12 | Ki | 1.3000 | 0.0270 | 3.6413 | 7.3000 | AID38398 |
| Trypsin-2 | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.0035 | 1.5846 | 4.4000 | AID44381 |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | IC50 (µMol) | 100.0000 | 0.0003 | 1.3833 | 8.4000 | AID36989 |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | IC50 (µMol) | 100.0000 | 0.0005 | 1.4835 | 7.8000 | AID36989 |
| 5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | IC50 (µMol) | 100.0000 | 0.0031 | 1.7360 | 7.8000 | AID36989 |
| 5-hydroxytryptamine receptor 1F | Rattus norvegicus (Norway rat) | IC50 (µMol) | 100.0000 | 0.0050 | 1.7962 | 7.8000 | AID36989 |
| Angiotensin-converting enzyme | Rattus norvegicus (Norway rat) | Ki | 1.3000 | 0.0001 | 1.9642 | 7.3000 | AID38398 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| digestion | Chymotrypsinogen A | Bos taurus (cattle) |
| antibiotic catabolic process | Beta-lactamase | Escherichia coli K-12 |
| response to antibiotic | Beta-lactamase | Escherichia coli K-12 |
| proteolysis | Trypsin-2 | Homo sapiens (human) |
| digestion | Trypsin-2 | Homo sapiens (human) |
| antimicrobial humoral response | Trypsin-2 | Homo sapiens (human) |
| extracellular matrix disassembly | Trypsin-2 | Homo sapiens (human) |
| positive regulation of cell growth | Trypsin-2 | Homo sapiens (human) |
| collagen catabolic process | Trypsin-2 | Homo sapiens (human) |
| positive regulation of cell adhesion | Trypsin-2 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| protein binding | Chymotrypsinogen A | Bos taurus (cattle) |
| serpin family protein binding | Chymotrypsinogen A | Bos taurus (cattle) |
| beta-lactamase activity | Beta-lactamase | Escherichia coli K-12 |
| hydrolase activity | Beta-lactamase | Escherichia coli K-12 |
| metalloendopeptidase activity | Trypsin-2 | Homo sapiens (human) |
| serine-type endopeptidase activity | Trypsin-2 | Homo sapiens (human) |
| calcium ion binding | Trypsin-2 | Homo sapiens (human) |
| protein binding | Trypsin-2 | Homo sapiens (human) |
| serine-type peptidase activity | Trypsin-2 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| extracellular region | Chymotrypsinogen A | Bos taurus (cattle) |
| serine protease inhibitor complex | Chymotrypsinogen A | Bos taurus (cattle) |
| outer membrane-bounded periplasmic space | Beta-lactamase | Escherichia coli K-12 |
| periplasmic space | Beta-lactamase | Escherichia coli K-12 |
| extracellular region | Trypsin-2 | Homo sapiens (human) |
| extracellular space | Trypsin-2 | Homo sapiens (human) |
| extracellular matrix | Trypsin-2 | Homo sapiens (human) |
| azurophil granule lumen | Trypsin-2 | Homo sapiens (human) |
| extracellular space | Trypsin-2 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID67675 | Compound was tested for its specificity against Elastase | 1998 | Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23 | Structure-based enhancement of boronic acid-based inhibitors of AmpC beta-lactamase. |
| AID38396 | Compound was tested for its specificity against AmpC beta-lactamase | 1998 | Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23 | Structure-based enhancement of boronic acid-based inhibitors of AmpC beta-lactamase. |
| AID38398 | Inhibitory activity against Escherichia coli AmpC beta-lactamase. | 1998 | Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23 | Structure-based enhancement of boronic acid-based inhibitors of AmpC beta-lactamase. |
| AID36989 | Compound was tested for its specificity against alpha-chymotrypsin | 1998 | Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23 | Structure-based enhancement of boronic acid-based inhibitors of AmpC beta-lactamase. |
| AID44381 | Compound was tested for its specificity against beta-trypsin | 1998 | Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23 | Structure-based enhancement of boronic acid-based inhibitors of AmpC beta-lactamase. |
| AID437830 | Inhibition of penicillin-resistant Streptococcus pneumoniae 5204 PBP2X assessed as residual activity at 500 uM preincubated for 4 hrs before addition of substrate mixture of (R)-[2-(benzoylamino)propionylsulfanyl]acetic acid and 5,5'-dithiobis(2-nitrobenz | 2009 | Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19 | Synthesis and evaluation of 3-(dihydroxyboryl)benzoic acids as D,D-carboxypeptidase R39 inhibitors. |
| AID437827 | Inhibition of penicillin-sensitive Streptococcus pneumoniae R6 PBP2X assessed as residual activity at 500 uM preincubated for 60 mins before addition of substrate mixture of (R)-[2-(benzoylamino)propionylsulfanyl]acetic acid and 5,5'-dithiobis(2-nitrobenz | 2009 | Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19 | Synthesis and evaluation of 3-(dihydroxyboryl)benzoic acids as D,D-carboxypeptidase R39 inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (66.67) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.25) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||